Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis

Joelle Bousaba; Kia Vosoughi; Saam Dilmaghani; Larry J. Prokop; Michael Camilleri

doi:10.2217/pgs-2022-0192

Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis

Joelle Bousaba, Kia Vosoughi, Saam Dilmaghani, Larry J. Prokop, Michael Camilleri

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

Abstract

Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.

Original language	English (US)
Pages (from-to)	283-295
Number of pages	13
Journal	Pharmacogenomics
Volume	24
Issue number	5
DOIs	https://doi.org/10.2217/pgs-2022-0192
State	Published - Apr 1 2023

Keywords

GLP-1 agonist
bupropion
gene
individualized
naltrexone
pharmacogenomic

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2022-0192

Cite this

@article{0919301f2a564ca4b81f5613559099ca,

title = "Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis",

abstract = "Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.",

keywords = "GLP-1 agonist, bupropion, gene, individualized, naltrexone, pharmacogenomic",

author = "Joelle Bousaba and Kia Vosoughi and Saam Dilmaghani and Prokop, {Larry J.} and Michael Camilleri",

note = "Publisher Copyright: {\textcopyright} 2023 Future Medicine Ltd.",

year = "2023",

month = apr,

day = "1",

doi = "10.2217/pgs-2022-0192",

language = "English (US)",

volume = "24",

pages = "283--295",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Pharmacogenetic interactions of medications administered for weight loss in adults

T2 - a systematic review and meta-analysis

AU - Bousaba, Joelle

AU - Vosoughi, Kia

AU - Dilmaghani, Saam

AU - Prokop, Larry J.

AU - Camilleri, Michael

PY - 2023/4/1

Y1 - 2023/4/1

N2 - Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.

AB - Aim: To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. Materials & methods: We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. Results: 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in CNR1, GLP-1R, MC4R, TCF7L2, CTRB1/2, ADIPOQ, SORCS1 and ANKK1 were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). CNR1 gene (rs1049353), GLP-1R gene (rs6923761, rs10305420), TCF7L2 gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Conclusion: Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.

KW - GLP-1 agonist

KW - bupropion

KW - gene

KW - individualized

KW - naltrexone

KW - pharmacogenomic

UR - http://www.scopus.com/inward/record.url?scp=85152629056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152629056&partnerID=8YFLogxK

U2 - 10.2217/pgs-2022-0192

DO - 10.2217/pgs-2022-0192

M3 - Review article

C2 - 36999540

AN - SCOPUS:85152629056

SN - 1462-2416

VL - 24

SP - 283

EP - 295

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 5

ER -

Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this